Literature DB >> 8198880

Serum Lp(a) lipoprotein concentration and outcome of thrombolytic treatment for myocardial infarction.

A D MBewu1, P N Durrington, M I Mackness, L Hunt, W H Turkie, J E Creamer.   

Abstract

BACKGROUND: Lp(a) lipoprotein has structural homology with plasminogen and has been shown to inhibit plasminogen activation in vitro.
OBJECTIVE: To determine whether the serum concentration of Lp(a) lipoprotein present when streptokinase was given in acute myocardial infarction influenced the outcome as judged by electrocardiographic methods. PATIENTS AND
DESIGN: Serum Lp(a) lipoprotein concentration was measured in 135 consecutive patients admitted with a diagnosis of acute myocardial infarction who received streptokinase treatment. Recovery from myocardial injury was assessed by the reduction in the sum of ST segment elevation measured from the J point (STJ) in the electrocardiogram immediately before streptokinase was given compared with that three hours later.
RESULTS: The serum Lp(a) lipoprotein concentrations were measured within 12 hours of the onset of symptoms of myocardial infarction and were higher than in healthy reference populations. Recovery from myocardial infarction could be assessed from the STJ in 116 patients (86% of the series). Those in whom it could not had bundle branch block, left ventricular hypertrophy, did not survive three hours, or had started intravenous nitrate treatment or some other clinical procedure before or at the time the second electrocardiogram was to be recorded. Patients with reductions in STJ after streptokinase that were > 4 mm (the median decrease) had mean (range) serum Lp(a) lipoprotein concentrations of 41.0 (0.8-220) mg/dl and those with a smaller reduction in STJ had concentrations of 29.1 (1.7-151) mg/dl. The difference was not statistically significant.
CONCLUSION: In this study Lp(a) lipoprotein concentration did not significantly influence the outcome of thrombolytic treatment with streptokinase.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8198880      PMCID: PMC483679          DOI: 10.1136/hrt.71.4.316

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  27 in total

1.  Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET).

Authors:  R G Wilcox; G von der Lippe; C G Olsson; G Jensen; A M Skene; J R Hampton
Journal:  Lancet       Date:  1988-09-03       Impact factor: 79.321

2.  Electrocardiographic prediction of coronary artery patency after thrombolytic treatment in acute myocardial infarction: use of the ST segment as a non-invasive marker.

Authors:  K J Hogg; R S Hornung; C A Howie; N Hockings; F G Dunn; W S Hillis
Journal:  Br Heart J       Date:  1988-10

3.  Assessment of jeopardized myocardium in patients with one-vessel disease.

Authors:  A S Iskandrian; R Lichtenberg; B L Segal; G S Mintz; E D Mundth; A H Hakki; D Kimbiris; C E Bemis; M N Croll; S A Kane
Journal:  Circulation       Date:  1982-02       Impact factor: 29.690

4.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

Authors:  J H Chesebro; G Knatterud; R Roberts; J Borer; L S Cohen; J Dalen; H T Dodge; C K Francis; D Hillis; P Ludbrook
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

5.  Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction.

Authors:  H D White; R M Norris; M A Brown; M Takayama; A Maslowski; N M Bass; J A Ormiston; T Whitlock
Journal:  N Engl J Med       Date:  1987-10-01       Impact factor: 91.245

6.  The immediate effect of streptokinase on serum lipoprotein(a) concentration and the effect of myocardial infarction on serum lipoprotein(a), apolipoproteins A1 and B, lipids and C-reactive protein.

Authors:  A D MBewu; P N Durrington; S Bulleid; M I Mackness
Journal:  Atherosclerosis       Date:  1993-10       Impact factor: 5.162

7.  Apolipoproteins (a), AI, and B and parental history in men with early onset ischaemic heart disease.

Authors:  P N Durrington; M Ishola; L Hunt; S Arrol; D Bhatnagar
Journal:  Lancet       Date:  1988-05-14       Impact factor: 79.321

8.  Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis.

Authors:  K A Hajjar; D Gavish; J L Breslow; R L Nachman
Journal:  Nature       Date:  1989-05-25       Impact factor: 49.962

9.  Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography.

Authors:  G H Dahlen; J R Guyton; M Attar; J A Farmer; J A Kautz; A M Gotto
Journal:  Circulation       Date:  1986-10       Impact factor: 29.690

10.  The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels.

Authors:  V W Armstrong; P Cremer; E Eberle; A Manke; F Schulze; H Wieland; H Kreuzer; D Seidel
Journal:  Atherosclerosis       Date:  1986-12       Impact factor: 5.162

View more
  1 in total

Review 1.  Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  J Lipid Res       Date:  2015-12-08       Impact factor: 5.922

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.